CL and ALB: Dividend Aristocrats That Hedge Funds Are Actively Backing

For investors seeking consistent income, dividend aristocrats—companies maintaining over 25 consecutive years of dividend increases—represent a compelling opportunity. Among these, Colgate-Palmolive (CL) and Albemarle (ALB) have emerged as particularly attractive holdings, commanding significant attention from institutional investors and earning strong analyst support. Understanding why these two stocks are capturing capital flows reveals important insights for income-focused portfolios.

Why CL Continues to Appeal to Income-Focused Investors

Colgate-Palmolive stands out as an exceptional dividend grower, having increased its payout for six consecutive decades. This extended track record of consistency demonstrates management’s confidence in the company’s cash generation capabilities. The consumer products company benefits from robust demand for its Oral Care division and Hill’s Pet Nutrition subsidiary—categories that show resilience across economic cycles.

The company’s strong brand portfolio provides additional cushion against inflationary pressures, allowing management room to implement strategic price increases when needed. This pricing power, combined with category leadership, positions CL favorably to sustain both top-line growth and margin expansion in the medium to long term.

Institutional Money Shows Growing Confidence in CL

Recent data from TipRanks’ Hedge Fund Trading Activity indicator reveals “Very Positive” momentum around CL stock. During the latest quarter, hedge funds collectively acquired approximately one million shares, signaling renewed enthusiasm from sophisticated investors. This accumulation pattern reflects more than just positive sentiment—it suggests conviction among professional money managers who carefully evaluate risk-reward dynamics.

Notable investors who increased their CL positions include Morningstar Investment Management’s Kunal Kapoor and Gotham Asset Management’s Joel Greenblatt, among other institutional players. This convergence of hedge fund buying activity provides third-party validation for the stock’s investment merits.

What the Street Consensus Shows for CL

Recent analyst reviews paint an encouraging picture for CL stock. The consensus leans moderately bullish, with five Buy and five Hold recommendations issued over recent months. This balanced recommendation mix translates into an overall “Moderate Buy” consensus.

The average price target among analysts stands at $84.70, implying approximately 21.9% appreciation potential from current levels. Additionally, CL carries a Smart Score of 9 out of 10 on TipRanks, a metric suggesting the stock possesses the characteristics to outperform the broader market ahead.

ALB: A Beneficiary of Structural Lithium Demand

Albemarle represents a different but equally compelling growth narrative. The company has maintained dividend growth for 29 consecutive years while securing a dominant position in the global lithium market. As demand for lithium accelerates due to electric vehicle adoption and battery storage expansion, ALB’s asset portfolio and production capabilities position it at the center of this secular trend.

The company’s diversified lithium access—spanning multiple geographic regions and extraction methods—provides supply stability and margin flexibility. These structural advantages translate into durable competitive positioning as lithium demand continues its upward trajectory.

Hedge Funds Are Accumulating ALB Shares

Similar to CL, ALB is attracting substantial institutional capital. The hedge fund community acquired approximately 665,100 shares during the latest quarter, according to TipRanks’ tracking data. The “Very Positive” signal in hedge fund activity suggests mounting confidence among professional investors.

Leaders from Coatue Management (Philippe Laffont) and Sheaff Brock Investment Advisors (David S. Gilreath) were among prominent fund managers who expanded their ALB positions, indicating conviction among multi-billion dollar investment operations.

Analyst Perspective on ALB’s Prospects

Analyst coverage for ALB reflects significant optimism. Over recent months, the stock has garnered 13 Buy recommendations, three Hold ratings, and just one Sell, resulting in a “Moderate Buy” consensus. This strong bullish tilt underscores confidence in both the company’s execution and the lithium market’s structural tailwinds.

The average price target of $262.53 implies approximately 71.5% upside potential from current levels—substantially more than CL’s projection. Notably, ALB holds a “Perfect 10” Smart Score on TipRanks, the highest possible rating, reinforcing the analyst community’s conviction about its forward trajectory.

The Dual Case for CL and ALB in Volatile Markets

Both Colgate-Palmolive and Albemarle demonstrate why dividend aristocrats command investor attention during uncertain periods. CL offers stability through brand moats and pricing power; ALB offers growth through exposure to secular lithium demand.

The convergence of institutional buying, strong analyst backing, and compelling fundamental narratives surrounding both CL and ALB suggests these holdings merit serious consideration for investors balancing income needs with capital appreciation potential. The fact that sophisticated hedge fund managers are deploying capital into both names provides additional confidence in their intermediate-term outlook.